Vernon Dialysis Center is a medicare approved dialysis facility center in Vernon Rockville, Connecticut and it has 22 dialysis stations. It is located in Tolland county at 460 Hartford Turnpike, Vernon Rockville, CT, 06066. You can reach out to the office of Vernon Dialysis Center at (860) 896-1537. This dialysis clinic is managed and/or owned by Davita. Vernon Dialysis Center has the following ownership type - Profit. It was first certified by medicare in September, 2006. The medicare id for this facility is 072529 and it accepts patients under medicare ESRD program.
Name | Vernon Dialysis Center |
---|---|
Location | 460 Hartford Turnpike, Vernon Rockville, Connecticut |
No. of Dialysis Stations | 22 |
Medicare ID | 072529 |
Managed By | Davita |
Ownership Type | Profit |
Late Shifts | Yes |
460 Hartford Turnpike, Vernon Rockville, Connecticut, 06066 | |
(860) 896-1537 | |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
NPI Number | 1942244363 |
Organization Name | Vernon Dialysis Center |
Doing Business As | Total Renal Care Inc |
Address | 460 Hartford Tpke Ste C Vernon, Connecticut, 06066 |
Phone Number | (860) 896-1537 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 79% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 9% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 74% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 14% |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 67% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 13% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 12% |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 83% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 17% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 19% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 12% |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Dialysis patients with Hemoglobin data | 57 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 16 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 77 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 723 |
Percentage of adult patients getting regular hemodialysis at the center | 96 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Adult patients getting regular peritoneal dialysis at the center | 25 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 257 |
Percentage of adult patients getting regular peritoneal dialysis at the center | 99 |
Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Vernon Dialysis Center with elevated calcium levels.
Patients with hypercalcemia | 104 |
Hypercalcemia patient months | 1020 |
Patients with Serumphosphor | 109 |
Patients with Serumphosphor less than 3.5 mg/dL | 6 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 34 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 66 |
Patient months included in arterial venous fistula and catheter summaries | 551 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 60 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 88 |
Hospitalization Rate in facility | 145.8 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 266.2 |
Hospitalization Rate: Lower Confidence Limit | 87.4 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Vernon Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 24.5 (As Expected) |
Readmission Rate: Upper Confidence Limit | 35.1 |
Readmission Rate: Lower Confidence Limit | 15.6 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Vernon Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .19 (Better than Expected) |
SIR: Upper Confidence Limit | .95 |
SIR: Lower Confidence Limit | .01 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Vernon Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 73 |
Transfusion Rate in facility | 23.8 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 69.1 |
Transfusion Rate: Lower Confidence Limit | 9.4 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Vernon Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 443 |
Mortality Rate in facility | 14.7 (As Expected) |
Mortality Rate: Upper Confidence Limit | 18.9 |
Mortality Rate: Lower Confidence Limit | 11.2 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago
Vernon Dialysis Center Location: 460 Hartford Turnpike, Vernon Rockville, Connecticut, 06066 Phone: (860) 896-1537 |
News Archive
Today, the International and American Associations for Dental Research published a paper titled "Global Burden of Oral Conditions in 1990-2010: A Systemic Analysis." The paper, written by lead author Wagner Marcenes, Queen Mary University, London, is published in the IADR/AADR Journal of Dental Research.
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
One in five South Australians will experience an unplanned hospitalization or emergency department presentation within 90 days of undertaking an aged care assessment, according to new research by the University of South Australia and the South Australian Health and Medical Research Institute.
Kaiser Health News provides a fresh perspective on health policy developments with "Second Opinion?" by Gary Varvel.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 2 days ago